Abstract | BACKGROUND: The no-reflow (NR) phenomenon exists despite percutaneous coronary intervention (PCI), and is especially prevalent in diabetics. The causes(s) of NR are not fully elucidated, but may be associated with impaired residual platelet and inflammatory reactivity during dual-antiplatelet therapy. OBJECTIVE: METHODS: Sixty diabetics with (n = 27) and without NR (n = 33) were prospectively enrolled. All patients were treated with clopidogrel and aspirin. Platelet and inflammatory biomarkers were assessed serially in the peripheral blood and right atrium before and after PCI and then at 24 h, 7 days and 30 days. RESULTS: CONCLUSION: An inadequate response to aspirin, but not to clopidogrel, may be associated with the occurrence of the NR phenomenon in diabetics with STEMI who have been treated with primary PCI.
|
Authors | Wiktor Kuliczkowski, Mariusz Gasior, Damian Pres, Jacek Kaczmarski, Anna Laszowska, Marta Szewczyk, Michal Hawranek, Mateusz Tajstra, Slawomir Zeglen, Lech Polonski, Victor L Serebruany |
Journal | Cardiology
(Cardiology)
Vol. 131
Issue 1
Pg. 41-50
( 2015)
ISSN: 1421-9751 [Electronic] Switzerland |
PMID | 25832492
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 S. Karger AG, Basel. |
Chemical References |
- Biomarkers
- Platelet Aggregation Inhibitors
- Clopidogrel
- Ticlopidine
- Aspirin
|
Topics |
- Aged
- Aspirin
(therapeutic use)
- Biomarkers
(blood)
- Clopidogrel
- Diabetes Complications
(blood, etiology)
- Drug Resistance
- Female
- Humans
- Inflammation
(blood)
- Male
- Middle Aged
- Myocardial Infarction
(complications, therapy)
- No-Reflow Phenomenon
(blood, etiology)
- Percutaneous Coronary Intervention
- Platelet Aggregation
- Platelet Aggregation Inhibitors
(therapeutic use)
- Ticlopidine
(analogs & derivatives, therapeutic use)
|